Report Sections

See All Reports

Coronavirus Infections (722) Severe Acute Respiratory Syndrome (493) Infection (402) Pneumonia (331) Communicable Diseases (176) Respiratory Distress Syndrome, Adult (161) Acute Lung Injury (126) Respiratory Distress Syndrome, Newborn (126) (114) Syndrome (106) Virus Diseases (85) Pneumonia, Viral (73) Critical Illness (63) Depression (62) Anxiety Disorders (44) Disease (39) Stress Disorders, Post-Traumatic (34) Emergencies (31) Respiratory Tract Infections (31) Inflammation (30) Neoplasms (30) Cardiovascular Diseases (29) Stress Disorders, Traumatic (29) Wounds and Injuries (29) Lung Injury (27) Stress, Psychological (27) Mental Disorders (26) Diabetes Mellitus (25) Hypoxia (25) Depressive Disorder (24) Thrombosis (23) Hypertension (22) Respiratory Tract Diseases (22) Acute Kidney Injury (21) Lung Diseases (21) Disease Progression (18) Olfaction Disorders (18) Embolism (16) Influenza, Human (16) Stroke (16) Arthritis (15) Pulmonary Embolism (15) Respiration Disorders (15) Blood Coagulation Disorders (14) HIV Infections (14) Hemostatic Disorders (14) Thromboembolism (14) Burnout, Psychological (13) Chronic Disease (13) Fibrosis (13) Lung Diseases, Obstructive (13) Multiple Sclerosis (13) Sclerosis (13) Cognitive Dysfunction (12) Diabetes Mellitus, Type 2 (12) Lung Diseases, Interstitial (12) Myocardial Infarction (12) Pulmonary Disease, Chronic Obstructive (12) Pulmonary Fibrosis (12) Respiratory Aspiration (12) Arthritis, Rheumatoid (11) Autism Spectrum Disorder (11) Brain Injuries (11) Chronic Pain (11) Heart Diseases (11) Kidney Diseases (11) Substance-Related Disorders (11) Venous Thrombosis (11) Crohn Disease (10) Diabetes Mellitus, Type 1 (10) Heart Failure (10) Infarction (10) Lung Neoplasms (10) Autistic Disorder (9) Dyspnea (9) Myocarditis (9) Obesity (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Brain Injuries, Traumatic (8) Carcinoma (8) Colitis (8) Colitis, Ulcerative (8) Depression, Postpartum (8) Liver Diseases (8) Renal Insufficiency, Chronic (8) Respiratory Syncytial Virus Infections (8) Rheumatic Diseases (8) Ulcer (8) Vitamin D Deficiency (8) Coronary Artery Disease (7) Coronary Disease (7) Dementia (7) Feeding and Eating Disorders (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Kidney Failure, Chronic (7) Parkinson Disease (7) Problem Behavior (7) Pulmonary Valve Insufficiency (7) Venous Thromboembolism (7) Burnout, Professional (6) Collagen Diseases (6) Frailty (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Ischemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Musculoskeletal Pain (6) Overweight (6) Parasomnias (6) Pediatric Obesity (6) Psychotic Disorders (6) RNA Virus Infections (6) Sepsis (6) Shock (6) Spinal Cord Injuries (6) Acute Coronary Syndrome (5) Alcohol Drinking (5) Alcoholism (5) Autoimmune Diseases (5) Breast Neoplasms (5) Carcinoma, Non-Small-Cell Lung (5) Child Development Disorders, Pervasive (5) Convalescence (5) Coronaviridae Infections (5) Cystic Fibrosis (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Dyssomnias (5) Gastroparesis (5) Hypersensitivity (5) Leukemia (5) Lymphopenia (5) Multiple Organ Failure (5) Myocardial Ischemia (5) Neurologic Manifestations (5) Osteoarthritis (5) Prostatic Neoplasms (5) Renal Insufficiency (5) Alzheimer Disease (4) Asthma (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Brain Diseases (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Deglutition Disorders (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Fibromyalgia (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Liver Cirrhosis (4) Metabolic Syndrome (4) Migraine Disorders (4) Mycobacterium Infections (4) Neoplasm Metastasis (4) (4) Pancreatic Neoplasms (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Apnea Syndromes (4) Sleep Initiation and Maintenance Disorders (4) Thrombophilia (4) Vascular Diseases (4) Weight Loss (4) Acquired Immunodeficiency Syndrome (3) Adenoviridae Infections (3) Appendicitis (3) Arrhythmias, Cardiac (3) Arthritis, Psoriatic (3) Asymptomatic Diseases (3) Bronchiectasis (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Chilblains (3) Common Cold (3) Cross Infection (3) Dermatitis (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Endometriosis (3) Fatigue (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Hemophilia A (3) Leukemia, Lymphoid (3) Macular Edema (3) Malnutrition (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Mucocutaneous Lymph Node Syndrome (3) (3) Nervous System Diseases (3) Neuroendocrine Tumors (3) Occupational Stress (3) Osteoarthritis, Knee (3) Ovarian Neoplasms (3) Panic Disorder (3) Paramyxoviridae Infections (3) Peripheral Arterial Disease (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Premature Birth (3) Psychological Trauma (3) Pulmonary Edema (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Schizophrenia (3) Seizures (3) Sleep Apnea, Obstructive (3) Sleep Wake Disorders (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Tobacco Use Disorder (3) Triple Negative Breast Neoplasms (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Amyotrophic Lateral Sclerosis (2) Anemia, Sickle Cell (2) Angina Pectoris (2) Angioedema (2) Angioedemas, Hereditary (2) Anxiety, Separation (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrial Fibrillation (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Clinical Deterioration (2) Cognition Disorders (2) Colorectal Neoplasms (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Dermatitis, Atopic (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Eczema (2) Emphysema (2) Endocrine System Diseases (2) Fatigue Syndrome, Chronic (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Gaucher Disease (2) Glioblastoma (2) Headache (2) Healthcare-Associated Pneumonia (2) Heart Defects, Congenital (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Huntington Disease (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypothermia (2) Hypoventilation (2) Idiopathic Pulmonary Fibrosis (2) Intervertebral Disc Degeneration (2) Intestinal Diseases (2) Ischemic Attack, Transient (2) Jaundice (2) Leukemia, Myeloid, Acute (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Mobility Limitation (2) Mood Disorders (2) Motor Neuron Disease (2) Multiple Myeloma (2) Multiple Sclerosis, Relapsing-Remitting (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Peripheral Vascular Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Psoriasis (2) Purpura, Thrombocytopenic, Idiopathic (2) Rare Diseases (2) Recurrence (2) Respiratory Sounds (2) Sarcoidosis (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Thoracic Diseases (2) Thrombocytopenia (2) Toxemia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Angina, Stable (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Back Pain (1) Bacteremia (1) Barotrauma (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamous Cell (1) Cardiovascular Abnormalities (1) Cataract (1) Celiac Disease (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Clostridium Infections (1) (1) Colonic Diseases (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) (1) Coronary Artery (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Calculus (1) Dental Plaque (1) Depressi (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Nephropathies (1) Diabetic Neuropathies (1) Diphtheria (1) (1) Down Syndrome (1) Dyspareunia (1) Emergence Delirium (1) Encephalitis (1) Endocarditis (1) Endophthalmitis (1) Endotoxemia (1) Enuresis (1) Epilepsy (1) Esophageal and Gastric Varices (1) Esophagitis, Peptic (1) Eye Diseases (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Fatty Liver (1) (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Fistula (1) Food Hypersensitivity (1) Fractures, Closed (1) Fractures, Stress (1) Gait Disorders, Neurologic (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Gout (1) (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis (1) Hepatitis A (1) Hepatitis C (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypertension, Pregnancy-Induced (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Hypotension (1) Iatrogenic Disease (1) Infant, Newborn, Diseases (1) Infec (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Low Back Pain (1) Lung (1) Lyme Disease (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth Diseases (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscle Spasticity (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1) Neuromyelitis Optica (1) Non-alcoholic Fatty Liver Disease (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis Media with Effusion (1) Overweig (1) Pain (1) Pain, Procedural (1) Pancreatitis (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pleuropneumonia (1) (1) (1) Pneumonia, Bacterial (1) Pneumonia, V (1) Pre-Eclampsia (1) Pregnancy in Diabetics (1) Preleukemia (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) (1) (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) (1) Scleroderma, Localized (1) Scleroderma, Systemic (1) Self-Injurious Behavior (1) Severe Acute Respiratory Syn (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Stenosis (1) Spondylarthritis (1) Spondylolisthesis (1) Status Epilepticus (1) Stillbirth (1) Stomatitis (1) Str (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Temporomandibular Joint Disorders (1) Temporomandibular Joint Dy (1) Temporomandibular Joint Dysfunction Syndrome (1) Thalassemia (1) Thrombophlebitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Ulce (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Ventricular Dysfunction, Right (1) Virus Dis (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D003092: Colitis

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (18)


Name (Synonyms) Correlation
drug1041 Diagnostic Test: serology test for COVID-19 Wiki 0.35
drug1045 Diagnostic test Covid-19 Wiki 0.35
drug2902 Risankizumab Wiki 0.35
Name (Synonyms) Correlation
drug958 Cytochrome P450 (CYP) Substrates Wiki 0.35
drug1036 Dexmethylphenidate Wiki 0.35
drug3592 Upadacitinib (ABT-494) Wiki 0.35
drug1039 Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta Wiki 0.35
drug878 Continuation of anti-TNF treatment Wiki 0.35
drug1074 Discontinuation of anti-TNF treatment Wiki 0.35
drug4090 risankizumab Wiki 0.35
drug1770 JNJ-66525433 Wiki 0.35
drug2336 Ontamalimab Wiki 0.35
drug1046 Diagnostic test for SARS-Cov2 for patients and health staff Wiki 0.35
drug1037 DiaNose Wiki 0.35
drug1047 Diagnostic test for detection of SARS-CoV-2 Wiki 0.35
drug1048 Dialectical Behavioral Therapy (DBT) Skills Wiki 0.35
drug4038 placebo for risankizumab Wiki 0.25
drug2505 Placebo Wiki 0.07

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D003093 Colitis, Ulcerative NIH 1.00
D014456 Ulcer NIH 0.82
D009336 Necrosis NIH 0.25
Name (Synonyms) Correlation
D015212 Inflammatory Bowel Diseases NIH 0.13
D003424 Crohn Disease NIH 0.11

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0002583 Colitis HPO 1.00
HP:0100279 Ulcerative colitis HPO 1.00
HP:0002037 Inflammation of the large intestine HPO 0.13
Name (Synonyms) Correlation
HP:0100280 Crohn's disease HPO 0.11

Clinical Trials

Navigate: Correlations   HPO

There are 8 clinical trials


1 A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.

NCT03006068
Conditions
  1. Ulcerative Colitis (UC)
Interventions
  1. Drug: Upadacitinib (ABT-494)
  2. Drug: Placebo
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Treatment-emergent adverse events are defined as events that begin or worsen either on or after the first dose of the study drug and within 30 days after the last dose of the study drug in the analysis period.

Measure: Assessing Treatment-Emergent Adverse Events

Time: Up to 288 Weeks
2 Continuing or Discontinuing Anti-tumor Necrosis Factor Treatment in Patients With Ulcerative Colitis in Clinical Remission: a Prospective Open Randomized Parallel-group Study

The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha (TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the option to restart treatment in the case of relapse, is non-inferior to continued anti-TNF treatment. Secondary objectives are to assess the efficacy and safety of restarting anti-TNF treatment after a relapse

NCT03011268
Conditions
  1. Colitis,Ulcerative
Interventions
  1. Other: Discontinuation of anti-TNF treatment
  2. Other: Continuation of anti-TNF treatment
MeSH:Colitis Colitis, Ulcerative Ulcer Necrosis
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 2 years of randomized treatment

Measure: Proportion of patients in sustained clinical remission

Time: 2 years

Secondary Outcomes

Description: Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 4 years of randomized treatment

Measure: Proportion of patients in sustained clinical remission

Time: 4 years

Description: Relapse time

Measure: Time from randomization to relapse

Time: 2 years

Description: Relapse time

Measure: Time from randomization to relapse

Time: 4 years

Description: Remission, but no need to restart anti-tnf therapy

Measure: Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy

Time: 2 years

Description: Remission, but no need to restart anti-tnf therapy

Measure: Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy

Time: 4 years

Description: Remission after relapse

Measure: Proportion of relapse patients achieving remission after anti-TNF restart

Time: 2 years

Description: Remission after relapse

Measure: Proportion of relapse patients achieving remission after anti-TNF restart

Time: 4 years

Description: Adverse events

Measure: Adverse events and serious adverse events frequency and severity

Time: 2 years

Description: Adverse events

Measure: Adverse events and serious adverse events frequency and severity

Time: 4 years
3 A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

NCT03259308
Conditions
  1. Ulcerative Colitis
Interventions
  1. Drug: Ontamalimab
  2. Drug: Placebo
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Remission is defined as a composite score of patient-reported symptoms using daily ediary and centrally read endoscopy as stool frequency subscore of 0 or 1 with at least a 1-point change from baseline, rectal bleeding subscore of 0 and endoscopic subscore of 0 or 1 (modified, excludes friability). The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); Physician global assessment (PGA: 0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Remission at Week 12

Time: Week 12

Secondary Outcomes

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Endoscopic Remission at Week 12

Time: Week 12

Description: Clinical remission is defined by stool frequency subscore of 0 or 1 with at least a 1-point change from baseline in stool frequency subscore, and rectal bleeding subscore of 0. The stool frequency subscore and rectal bleeding subscore range from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Clinical Remission at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Clinical response (composite) is defined as a decrease from baseline in the composite score of patient-reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding greater than or equal to (>=) 1 point or a subscore for rectal bleeding less than or equal to (<=) 1. The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Response (Composite) at Week 12

Time: Week 12

Description: Mucosal healing is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability) and centrally read Geboes score of <=2. The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Mucosal Healing at Week 12

Time: Week 12

Description: Remission is defined as a total mayo score of less than or equal to <=2 with no individual subscore (stool frequency, rectal bleeding, endoscopy [modified, excludes friability], and PGA) exceeding 1, at the Week 12. The total mayo score ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Remission Based on Total Mayo Score at Week 12

Time: Week 12

Description: Clinical response (Mayo) is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding >=1 point or an absolute subscore for rectal bleeding <=1. The total mayo score ranges from 0 to 12 points and consists of the following 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Clinical Response Based on Total Mayo Score at Week 12

Time: Week 12

Description: The partial mayo score ranges from 0 to 9 points and consists of the following 3 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); PGA (0-3). The partial Mayo score does not include the endoscopy subscore. Here participants with partial Mayo score <= 2 with no individual subscore >1 at the Week 4, 8, and 12 will be assessed.

Measure: Number of Participants With Partial Mayo Score Less than or Equal to (<=) 2 with no Individual Subscore Greater than (>) 1 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Here number of participants with endoscopic remission at week 12 with a subscore of 0 will be assessed.

Measure: Number of Participants with Endoscopic Remission at Week 12 With Endoscopic Subscore of 0

Time: Week 12

Description: Clinical remission with both rectal bleeding and stool frequency subscores of 0 at week 4, 8, 12 will be assessed. The stool frequency subscore and rectal bleeding subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Remission With Both Rectal Bleeding and Stool Frequency Subscores of 0 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Deep remission is defined as both endoscopic and rectal bleeding subscores of 0, and stool frequency subscore <=1 and a centrally read Geboes score of <=2.. The stool frequency subscore, rectal bleeding subscore and endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Deep Remission at Week 12

Time: Week 12

Description: Participants will be asked to record the abdominal pain worst severity using 0-10 numeric rating scale, with 0 anchor at "No pain" and 10 at "Worst Imaginable Pain" as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Abdominal Pain Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the diarrhea frequency (enter number of loose or watery bowel movements) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Diarrhea Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the urgency frequency (enter number of bowel movements with urgency) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Urgency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the stool frequency (enter number of bowel movements passed) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Stool Frequency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the rectal bleeding severity and frequency (enter number of bowel movements with blood) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Rectal Bleeding Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The total sign/symptom score (average of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency) ranges from 0 to 10 with higher scores indicating higher severity.

Measure: Change From Baseline Total Sign/Symptom Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The IBDQ is a psychometrically validated participant-reported outcome (PRO) instrument for measuring the disease-specific HRQL in participants with inflammatory bowel disease, including UC. The IBDQ consists of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better HRQL. A score of at least 170 corresponds to clinical remission and an increase of at least 16 points is considered to indicate a clinically meaningful improvement.

Measure: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domains and Total Absolute Scores in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 8, 12

Time: Baseline, Week 8, 12

Description: The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQL.

Measure: Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores and Individual Domain Scores) at Week 12

Time: Baseline, Week 12

Description: Incidence of hospitalizations during the entire study period will be assessed.

Measure: Incidence of Hospitalizations

Time: From start of study up to follow up (Week 29)

Description: Incidence of total inpatient days during the entire study period will be assessed.

Measure: Incidence of Total Inpatient Days

Time: From start of study up to follow up (Week 29)
4 A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)

The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of participant-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

NCT03259334
Conditions
  1. Ulcerative Colitis
Interventions
  1. Drug: Ontamalimab
  2. Other: Placebo
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Remission is defined as a composite score of participant-reported symptoms using daily e-diary and centrally read endoscopy as stool frequency subscore of 0 or 1 with at least a 1-point change from baseline, rectal bleeding subscore of 0 and endoscopic subscore of 0 or 1 (modified, excludes friability). The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); Physician global assessment (PGA: 0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Remission at Week 12

Time: Week 12

Secondary Outcomes

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Endoscopic Remission at Week 12

Time: Week 12

Description: Clinical remission is defined by stool frequency subscore of 0 or 1 with at least a 1-point change from baseline in stool frequency subscore, and rectal bleeding subscore of 0. The stool frequency subscore and rectal bleeding subscore range from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Clinical Remission at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Clinical response (composite) is defined as a decrease from baseline in the composite score of participant-reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding greater than or equal to (>=) 1 point or a subscore for rectal bleeding less than or equal to (<=) 1. The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Response (Composite) at Week 12

Time: Week 12

Description: Mucosal healing is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability) and centrally read Geboes score of <=2. The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Mucosal Healing at Week 12

Time: Week 12

Description: Remission is defined as a total mayo score of less than or equal to <=2 with no individual subscore (stool frequency, rectal bleeding, endoscopy [modified, excludes friability], and physician's global assessment) exceeding 1, at the Week 12. The total mayo score ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Remission Based on Total Mayo Score at Week 12

Time: Week 12

Description: Clinical response (Mayo) is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding >=1 point or an absolute subscore for rectal bleeding <=1. The total mayo score ranges from 0 to 12 points and consists of the following 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Clinical Response Based on Total Mayo Score at Week 12

Time: Week 12

Description: The partial mayo score ranges from 0 to 9 points and consists of the following 3 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); PGA (0-3). The partial Mayo score does not include the endoscopy subscore. Number of participants with partial mayo score <=2 with no individual subscore >1 at the Week 4, 8, 12 will be assessed.

Measure: Number of Participants With Partial Mayo Score Less than or Equal (<=) 2 with no individual subscore Greater than (>) 1 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Here number of participants with endoscopic remission at week 12 with a subscore of 0 will be assessed.

Measure: Number of Participants with Endoscopic Remission at Week 12 With Endoscopic Subscore of 0

Time: Week 12

Description: Clinical remission with both rectal bleeding and stool frequency subscores of 0 at week 4, 8, 12 will be assessed. The stool frequency subscore and rectal bleeding subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Remission With Both Rectal Bleeding and Stool Frequency Subscores of 0 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Deep remission is defined as both endoscopic and rectal bleeding subscores of 0, and stool frequency subscore <=1 and a centrally read Geboes score of <=2.. The stool frequency subscore, rectal bleeding subscore and endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Deep Remission at Week 12

Time: Week 12

Description: Participants will be asked to record the abdominal pain worst severity using 0-10 numeric rating scale, with 0 anchor at "No pain" and 10 at "Worst Imaginable Pain" as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Abdominal Pain Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the diarrhea frequency (enter number of loose or watery bowel movements) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Diarrhea Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the urgency frequency (enter number of bowel movements with urgency) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Urgency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the stool frequency (enter number of bowel movements passed) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Stool Frequency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the rectal bleeding severity and frequency (enter number of bowel movements with blood) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Rectal Bleeding Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The total sign/symptom score (average of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency) ranges from 0 to 10 with higher scores indicating higher severity.

Measure: Change From Baseline Total Sign/Symptom Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The IBDQ is a psychometrically validated participant-reported outcome (PRO) instrument for measuring the disease-specific HRQL in participants with inflammatory bowel disease, including UC. The IBDQ consists of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better HRQL. A score of at least 170 corresponds to clinical remission and an increase of at least 16 points is considered to indicate a clinically meaningful improvement.

Measure: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domains and Total Absolute Scores in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 8, 12

Time: Baseline, Week 8, 12

Description: The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQL.

Measure: Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores and Individual Domain Scores) at Week 12

Time: Baseline, Week 12

Description: Incidence of hospitalizations during the entire study period will be assessed.

Measure: Incidence of Hospitalizations

Time: From start of study up to follow up (Week 29)

Description: Incidence of total inpatient days during the entire study period will be assessed.

Measure: Incidence of Total Inpatient Days

Time: From start of study up to follow up (Week 29)
5 A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studies: Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic.

NCT03398135
Conditions
  1. Ulcerative Colitis (UC)
Interventions
  1. Drug: risankizumab
  2. Drug: placebo for risankizumab
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score

Time: Week 52

Secondary Outcomes

Description: Endoscopic remission per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Remission

Time: Week 52

Description: Clinical remission per full Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline (of Induction)

Time: Week 52

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use, Remained Corticosteroid Free for 90 days, and Achieved Clinical Remission per Adapted Mayo Score in Participants Taking Steroids at Baseline (of induction).

Time: Week 52

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with a Clinical Remission at Week 0

Time: Week 52

Description: Participants who discontinued corticosteroid use.

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use in Participants who were Taking Steroids at Baseline (of induction)

Time: Week 52

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Improvement in Participants with Endoscopic Improvement at Week 0

Time: Week 52

Description: Clinical response per Adapted Mayo score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Response per Adapted Mayo Score

Time: Week 52

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Improvement

Time: Week 52

Description: Participants with an event that results in admission to the hospital.

Measure: Sub-Study 1: Percentage of Participants with Hospitalization

Time: Through Week 52

Description: The UC-SQ is a patient questionnaire to assess severity of ulcerative colitis symptoms.

Measure: Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)

Time: Week 0 to Week 52

Description: Histologic remission per Geboes Score.

Measure: Sub-Study 1: Percentage of Participants with Histologic Remission

Time: Week 52

Description: Mucosal healing defined as endoscopic and histologic remission.

Measure: Sub-Study 1: Percentage of Participants with Mucosal Healing

Time: Week 52

Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.

Measure: Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

Time: Week 0 to Week 52

Description: Participants who underwent surgery related to UC.

Measure: Sub-Study 1: Percentage of Participants with Ulcerative Colitis (UC)-Related Surgeries

Time: Through Week 52

Description: The SF-36 is an indicator of overall health status.

Measure: Sub-Study 1: Change in 36-Item Short Form Health Status Survey (SF-36)

Time: Week 0 to Week 52

Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

Measure: Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

Time: Week 0 to Week 52

Description: The SFS, RBS, and endoscopic subscore describe disease severity.

Measure: Sub-Study 1: Percentage of Participants with Stool Frequency Subscore (SFS), Rectal Bleeding Subscore (RBS), and Endoscopic Subscore of 0

Time: At Week 52

Description: The Stool Frequency Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Stool Frequency Subscore indicates improvement.

Measure: Sub-Study 1: Percentage of Participants with Stool Frequency Subscore (SFS) ≤ 1

Time: Through Week 52

Description: The Rectal Bleeding Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Rectal Bleeding Subscore indicates improvement.

Measure: Sub-Study 1: Percentage of Participants with Rectal Bleeding Subscore (RBS) = 0

Time: Through Week 52

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS.

Measure: Sub-study 1: Change from Baseline of Induction in Partial Adapted Mayo Score

Time: Through Week 52

Description: The Full Mayo Score ranges determines disease severity. A negative change in Full Mayo Score indicates improvement.

Measure: Sub-Study 1: Change in Full Mayo Score

Time: Week 0 to Week 52

Description: The Stool Frequency Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Stool Frequency Subscore indicates improvement.

Measure: Sub-Study 1: Change in SFS

Time: Week 0 to Week 52

Description: The Rectal Bleeding Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Rectal Bleeding Subscore indicates improvement.

Measure: Sub-Study 1: Change in RBS

Time: Week 0 to Week 52

Description: High sensitivity C-reactive protein was analyzed by a central laboratory. The median percent change from week 0 in CRP is assessed at each time point.

Measure: Sub-Study 1: Change in High Sensitivity C-reactive Protein (hs-CRP)

Time: Week 0 to Week 52

Description: Stool samples were analyzed by a central laboratory for fecal calprotectin (FCP)qualitative measurement. Results are reported for participants in each category.

Measure: Sub-Study 1: Change in Fecal Calprotectin (FCP)

Time: Week 0 to Week 52

Description: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is defined as an assessment of the endoscopy findings scoring system for additional exploratory analyses.

Measure: Sub-Study 1: Change from Baseline in Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

Time: At Week 52

Description: The European Quality of Life 5 Dimensions (EQ-5D-5L) is a standardized instrument used to measure health-related quality of life that can be used in a wide range of health conditions and treatments.

Measure: Sub-Study 1: Change in European Quality of Life 5 Dimensions (EQ-5D-5L)

Time: Week 0 to Week 52

Description: The WPAI UC questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis. The self-administered questionnaire measures the effect of the participant's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

Measure: Sub-Study 1: Change in Work Productivity and Impairment Questionnaire - UC (WPAI UC)

Time: Week 0 to Week 52

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS.

Measure: Sub-study 1: Time to Loss of Clinical Response per Partial Adapted Mayo in Patients with Response per Partial Adapted Mayo

Time: At Week 0

Description: The PGIS is a response scale that describes the severity of the participants disease.

Measure: Sub-Study 1: Change in Patient Global Impression of Severity (PGIS)

Time: Week 0 to Week 52

Description: The PGIC is a response scale. The participant will be asked by the Investigator or qualified designee to rate their change in their disease status.

Measure: Sub-Study 1: Change in Patient Global Impression of Change (PGIC) scores

Time: Through Week 52

Description: Participants who discontinued corticosteroid use, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 52

Description: Clinical remission per Adapted Mayo score, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use and Achieved Clinical Remission, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 52

Description: Clinical remission per Adapted Mayo score, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use for 90 Days and Achieved Clinical Remission, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 52

Description: Clinical remission per Adapted Mayo score, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use for 90 Days and SFS ≤ 1 (and not Worse than Baseline of Induction) and RBS = 1 and Achieved Clinical Remission, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 52

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS.

Measure: Sub-Study 3: Percentage of Participants with Clinical Response per Partial Adapted Mayo Score

Time: Through Week 300

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 3: Percentage of Participants with Clinical Remission per Adapted Mayo Score with Endoscopy

Time: Through Week 300

Description: Clinical response per Adapted Mayo score.

Measure: Sub-Study 3: Percentage of Participants with Clinical Response per Adapted Mayo Score with Endoscopy

Time: Through Week 300

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS.

Measure: Sub-Study 3: Time to Loss of Clinical Response per Partial Mayo Score

Time: Through Week 300

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 3: Time to Loss of Clinical Remission per Adapted Mayo Score with Endoscopy

Time: Through Week 300

Description: Clinical response per Adapted Mayo score.

Measure: Sub-Study 3: Time too Loss of Clinical Response per Adapted Mayo Score with Endoscopy

Time: Through Week 300

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 3: Percentage of Participants Who Discontinued Corticosteroid Use with Clinical Response per Partial Adapted Mayo Score in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 300

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 3: Percentage of Participants with Endoscopic Improvement

Time: Through Week 300

Description: Endoscopic remission per endoscopy subscore.

Measure: Sub-Study 3: Percentage of Participants with Endoscopic Remission

Time: Through Week 300

Description: Mucosal healing defined as endoscopic and histologic remission.

Measure: Sub-Study 3: Percentage of Participants with Mucosal Healing

Time: Through Week 300

Description: Histologic remission per Geboes Score.

Measure: Sub-Study 3: Percentage of Participants with Histologic Remission

Time: Through Week 300

Description: The UC-SQ is a patient questionnaire to assess severity of ulcerative colitis symptoms.

Measure: Sub-Study 3: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)

Time: Week 0 to Week 300

Description: Participants with an event that results in admission to the hospital.

Measure: Sub-Study 3: Percentage of Participants with Hospitalization

Time: Through Week 300

Description: Participants who underwent surgery related to UC.

Measure: Sub-Study 3: Percentage of Participants with Ulcerative Colitis (UC)-Related Surgeries

Time: Through Week 300

Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

Measure: Sub-Study 3: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

Time: Week 0 to Week 300

Description: The SF-36 is an indicator of overall health status.

Measure: Sub-Study 3: Change in 36-Item Short Form Health Status Survey (SF-36)

Time: Week 0 to Week 300

Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.

Measure: Sub-Study 3: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

Time: Through Week 300

Description: The WPAI UC questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis. The self-administered questionnaire measures the effect of the participant's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

Measure: Sub-Study 3: Change in Work Productivity and Impairment Questionnaire - UC (WPAI UC)

Time: Through Week 300

Description: The European Quality of Life 5 Dimensions (EQ-5D-5L) is a standardized instrument used to measure health-related quality of life that can be used in a wide range of health conditions and treatments.

Measure: Sub-Study 3: Change in European Quality of Life 5 Dimensions (EQ-5D-5L)

Time: Through Week 300

Description: The Rectal Bleeding Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Rectal Bleeding Subscore indicates improvement.

Measure: Sub-Study 3: Change in RBS

Time: Through Week 300

Description: The Stool Frequency Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Stool Frequency Subscore indicates improvement.

Measure: Sub-Study 3: Change in SFS

Time: Through Week 300

Description: Stool samples were analyzed by a central laboratory for fecal calprotectin (FCP)qualitative measurement. Results are reported for participants in each category.

Measure: Sub-Study 3: Change in Fecal Calprotectin (FCP)

Time: Through Week 300

Description: High sensitivity C-reactive protein was analyzed by a central laboratory. The median percent change from week 0 in CRP is assessed at each time point.

Measure: Sub-Study 3: Change in High Sensitivity C-reactive Protein (hs-CRP)

Time: Through Week 300

Description: The PGIS is a response scale that describes the severity of the participants disease.

Measure: Sub-Study 3: Change in Patient Global Impression of Severity (PGIS)

Time: Week 0 to Week 300

Description: The PGIC is a response scale. The participant will be asked by the Investigator or qualified designee to rate their change in their disease status.

Measure: Sub-Study 3: Change in Patient Global Impression of Change (PGIC) scores

Time: Through Week 300

Description: Participants who discontinued corticosteroid use, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 3: Percentage of Participants Who Discontinued Corticosteroid Use, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 300
6 A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study will evaluate the effect of repeated infusions of risankizumab on the pharmacokinetics of sensitive probe substrates of Cytochrome P450 (CYP) enzymes in participants with moderately to severely active UC or CD. Risankizumab is an investigational drug being developed to treat trial participants with inflammatory diseases such as UC and CD. The study is split into two periods. In Period 1, participants will receive single oral doses of CYP sensitive probes and in Period 2, participants will receive risankizumab followed by single oral doses of CYP sensitive probes. Around 20 adult participants with moderately to severely active CD or UC will be enrolled in the study across multiple sites worldwide. In Period 1, participants will receive oral doses of CYP sensitive probes on Day 1. In Period 2, participants will receive risankizumab by intravenous (IV) infusion on Days 1, 29 and 57 followed by oral CYP sensitive probes on Day 64. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.

NCT04254783
Conditions
  1. Ulcerative Colitis (UC)
  2. Crohn's Disease
Interventions
  1. Drug: Risankizumab
  2. Drug: Cytochrome P450 (CYP) Substrates
MeSH:Crohn Disease Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Crohn's disease Ulcerative colitis

Primary Outcomes

Description: Maximum observed plasma concentration (Cmax) of Midazolam

Measure: Maximum Observed Plasma Concentration (Cmax) of Midazolam

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Midazolam

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Midazolam

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Midazolam

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Midazolam

Measure: Terminal Phase Elimination Rate Constant (β) of Midazolam

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Midazolam

Measure: Terminal Phase Elimination Half-Life (t1/2) of Midazolam

Time: Up to 71 Days

Description: Maximum observed plasma concentration (Cmax) of Caffeine

Measure: Maximum Observed Plasma Concentration (Cmax) of Caffeine

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Caffeine

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Caffeine

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Caffeine

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Caffeine

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Caffeine

Measure: Terminal Phase Elimination Rate Constant (β) of Caffeine

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Caffeine

Measure: Terminal Phase Elimination Half-Life (t1/2) of Caffeine

Time: Up to 71 Days

Description: Maximum observed plasma concentration (Cmax) of Warfarin

Measure: Maximum Observed Plasma Concentration (Cmax) of Warfarin

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Warfarin

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Warfarin

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Warfarin

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Warfarin

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Warfarin

Measure: Terminal Phase Elimination Rate Constant (β) of Warfarin

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Warfarin

Measure: Terminal Phase Elimination Half-Life (t1/2) of Warfarin

Time: Up to 71 Days

Description: Maximum observed plasma concentration (Cmax) of Omeprazole

Measure: Maximum Observed Plasma Concentration (Cmax) of Omeprazole

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Omeprazole

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Omeprazole

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Omeprazole

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Omeprazole

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Omeprazole

Measure: Terminal Phase Elimination Rate Constant (β) of Omeprazole

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Omeprazole

Measure: Terminal Phase Elimination Half-Life (t1/2) of Omeprazole

Time: Up to 71 Days

Description: Maximum observed plasma concentration (Cmax) of Metoprolol

Measure: Maximum Observed Plasma Concentration (Cmax) of Metoprolol

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Metoprolol

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Metoprolol

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Metoprolol

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Metoprolol

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Metoprolol

Measure: Terminal Phase Elimination Rate Constant (β) of Metoprolol

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Metoprolol

Measure: Terminal Phase Elimination Half-Life (t1/2) of Metoprolol

Time: Up to 71 Days
7 PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis: A Multi-centre Observational Case- Control Study

Whether the perceived changes in management of Acute Severe Ulcerative Colitis during the COVID pandemic are widespread, and whether they have any impact on patient outcomes

NCT04411784
Conditions
  1. Inflammatory Bowel Diseases
  2. COVID
MeSH:Colitis Colitis, Ulcerative Inflammatory Bowel Diseases
HPO:Colitis Inflammation of the large intestine Ulcerative colitis

Primary Outcomes

Description: The need for in-hospital colectomy or rescue therapy

Measure: Primary outcome measure: The need for in-hospital colectomy or rescue therapy

Time: 3 months

Secondary Outcomes

Description: Duration and type/route of steroid use

Measure: 2.1: Duration and type/route of steroid use

Time: 3 months

Description: 30 day colectomy free survival rates

Measure: 2.2: 30 day colectomy free survival rates

Time: 3 months

Description: Covid-19 infection rates

Measure: 2.3: Covid-19 infection rates

Time: 3 months

Description: Rate of Rescue therapy use

Measure: 2.4: Rate of Rescue therapy use

Time: 3 months

Description: Duration of hospital stay

Measure: 2.5: Duration of hospital stay

Time: 3 months

Description: Admission severity scoring

Measure: 2.6: Admission severity scoring

Time: 3 months

Description: Readmission rates

Measure: 2.7: Readmission rates

Time: 3 months
8 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Participants and Multiple Dose Study in Participants With Ulcerative Colitis to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-66525433

The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared with placebo after administration of: 1) single ascending oral doses of JNJ 66525433 administered to healthy participants (Part 1), 2) multiple, ascending oral doses of JNJ 66525433, administered to healthy participants once daily over 14 consecutive days (Part 2), and 3) multiple oral doses of JNJ 66525433, administered once daily over 14 consecutive and once daily over 42 consecutive days in participants with ulcerative colitis (UC) (Part 3).

NCT04457960
Conditions
  1. Healthy
  2. Colitis, Ulcerative
Interventions
  1. Drug: JNJ-66525433
  2. Drug: Placebo
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Any AE occurring at or after the initial administration of study intervention through the day of last dose plus 30 days will be considered as TEAE.

Measure: Part 1, 2 and 3: Number of Participants with Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability

Time: Up to 224 Days

Description: Number of participants with vital sign abnormalities (temperature), pulse/heart rate, respiratory rate and blood pressure) will be reported.

Measure: Part 1, 2 and 3: Number of Participants with Vital Sign Abnormalities

Time: Up to 224 Days

Description: Number of participants with physical examination abnormalities will be reported.

Measure: Part 1, 2 and 3: Number of Participants with Physical Examination Abnormalities

Time: Up to 224 Days

Description: Number of participants with clinical laboratory abnormalities (serum chemistry, hematology and urinalysis) will be reported.

Measure: Part 1, 2 and 3: Number of Participants with Clinical Laboratory Abnormalities

Time: Up to 224 Days

Description: Number of participants with ECG abnormalities will be reported.

Measure: Part 1, 2 and 3: Number of Participants with Electrocardiogram (ECG) Abnormalities

Time: Up to 224 Days

Secondary Outcomes

Description: Plasma concentrations of JNJ-66525433 will be reported.

Measure: Part 1, 2 and 3: Plasma Concentrations of JNJ-66525433

Time: Up to 224 Days

Description: Plasma concentrations of JNJ-66525433 after fasted or fed dosing will be reported.

Measure: Part 1: Plasma Concentrations of JNJ-66525433 After Fasted or Fed Dosing

Time: Up to Day 14

Description: Mayo scoring system is used for assessment of ulcerative colitis activity. The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings) each ranges from 0 to 3. The Mayo score is calculated as the sum of these 4 subscores and can range between 0 and 12, where higher score indicates severe disease.

Measure: Part 3: Mayo Score

Time: Up to Day 84

Description: Partial Mayo score is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, and physician's global assessment) and ranges from 0 to 9 points. Higher score indicates severe disease.

Measure: Part 3: Partial Mayo Score

Time: Up to Day 70

Description: Endoscopy sub-score ranges from 0 to 3 where; 0 = normal or inactive disease; 1 = mild disease (erythema, decreased vascular pattern, mild friability); 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions); 3 = severe disease (spontaneous bleeding, ulceration).

Measure: Part 3: Endoscopic Subscore

Time: Up to Day 84

Description: IBDQ18 is a validated, 32-item, self-reported questionnaire for participants with inflammatory bowel disease (IBD) that will be used to evaluate the disease-specific health-related quality of life across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

Measure: Part 3: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

Time: Days 1, 7, 14, 28, 43, 70 and 84

Description: Levels of mRNA knockdown will be reported to assess target engagement in biopsy tissue by dose level over time.

Measure: Part 2 and 3: Target Engagement of Messenger Ribonucleic Acid (mRNA) Levels

Time: Up to 182 Days

Description: Tissue biopsy concentrations of JNJ-66525433 will be reported.

Measure: Part 2 and 3: Tissue Biopsy JNJ-66525433 Concentrations

Time: Up to 182 Days

HPO Nodes


Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,180 reports on interventions/drugs

MeSH

691 reports on MeSH terms

HPO

263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook